Moreover, our analysis demonstrates that an ALC ≥ 0.2 G/L, AFP, and the administration of a GTX combined with G-CSF are independent factors associated with reduced 28-day mortality in pediatric patients with acute leukemia and candidemia following intensive chemotherapy. This evidence concerns the gene AFP and acute leukemia.